David R. Liu - 30 Jun 2025 Form 4 Insider Report for Prime Medicine, Inc. (PRME)

Reporting relationship: 10%+ Owner
Issuer ticker: PRME
Reported as of: 30 Jun 2025
Net transaction value: +$52,830
SEC form: 4
Accepted by SEC: 01 Jul 2025, 16:03:52 UTC
Prior SEC filing: 23 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Ryan Brown, attorney-in-fact

Key filing fact

David R. Liu filed Form 4 for Prime Medicine, Inc. (PRME) on 01 Jul 2025.

Key facts

This page summarizes David R. Liu's Form 4 filing for Prime Medicine, Inc. (PRME).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Jul 2025, 16:03.

Change

Previous filing in this sequence was filed on 23 Jun 2025.
Current net transaction value: +$52,830.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001664439 Primary reporting owner

Liu David R.

Relationship: 10%+ Owner
Address: C/O PRIME MEDICINE, INC., 60 FIRST STREET, CAMBRIDGE
Signature: /s/ Ryan Brown, attorney-in-fact
Signature date: 01 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PRME transaction

Common Stock

Purchase

Transaction value: $52,830
Shares: +21,000
Change %: +0.1%
Price: $2.52
Shares after: 20,240,945
Date: 30 Jun 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025.

Footnote F2

The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.44 to $2.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.